NLSPW

25.00% 0.0008

Dopo l'orario di chiusura: .01 0.006 +150.00%

Nls Pharmaceutics Ag (NLSPW)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Nls Pharmaceutics Ag Stock (NLSPW) Company Profile

Nls Pharmaceutics Ag

Healthcare (1150)

Biotechnology (676)

41 44 512 21 50

The Circle 6, Zurich

Prossima data di guadagno

Ultimi documenti SEC

NLSPW's Discussions on Twitter

Confronta NLSPW con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NLSPW Nls Pharmaceutics Ag	0.004	0	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	500.19	127.64B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	603.58	65.95B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	656.65	37.92B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	273.55	32.98B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	254.16	26.92B	3.81B	-644.79M	-669.77M	-6.24

Nls Pharmaceutics Ag Borsa (NLSPW) Ultime notizie

Nls Pharmaceutics Ag Azioni (NLSPW) Dati Finanziari

Non sono disponibili dati finanziari per Nls Pharmaceutics Ag (NLSPW). Controlla altri titoli per ulteriori informazioni.

Nls Pharmaceutics Ag (NLSPW)

Nls Pharmaceutics Ag Stock (NLSPW) Company Profile

Confronta NLSPW con altri titoli

Nls Pharmaceutics Ag Borsa (NLSPW) Ultime notizie

Pre-market Movers: STSS, THRD, PTN, VRAX... - RTTNews

Press Release Distribution & PR Platform - ACCESS Newswire

NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine

NLS Pharmaceutics Study Suggests Mazindol May Help Treat Fentanyl Use Disorder - marketscreener.com

NLS Pharmaceutics Reports Positive Results in Fentanyl Study - TipRanks

Nls Pharmaceutics Announces Positive Results From Study Ko-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward In Animal Models - MarketScreener

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models - marketscreener.com

Kadimastem Ltd. announced that it expects to receive ILS 2 million in funding. - marketscreener.com

NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest - ACCESS Newswire

NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN

Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - ACCESS Newswire

NLS Pharmaceutics secures $2M for Kadimastem merger - Investing.com

NLS Pharmaceutics secures $2M for Kadimastem merger By Investing.com - Investing.com Canada

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - StreetInsider.com

NLSP stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa

NLSP stock touches 52-week low at $1.47 amid market challenges - Investing.com India

NLS Pharmaceutics Ltd. (NASDAQ:NLSPW) Short Interest Down 31.6% in February - Defense World

NLS Pharmaceutics announces merger with Kadimastem - Investing.com India

NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com UK

NLS Pharmaceutics CEO Issues Letter to Shareholders - Yahoo Finance

Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - Marketscreener.com

NLSP stock touches 52-week low at $1.71 amid steep annual decline By Investing.com - Investing.com South Africa

NLSP stock touches 52-week low at $1.71 amid steep annual decline - Investing.com India

NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq - accessnewswire.com

NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement - ACCESS Newswire

AEX-2 increases total wake duration in mouse model - BioWorld Online

NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment - ACCESS Newswire

NLS Pharmaceutics reports progress in narcolepsy treatment By Investing.com - Investing.com South Africa

NLS Pharmaceutics reports progress in narcolepsy treatment - Investing.com

Pre-IND meeting guides path forward for ITOL-102 for type 1 diabetes - BioWorld Online

NLS Pharmaceutics and Partners Achieve Milestone in Diabetes Treatment Development - MSN

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment - Yahoo Finance

NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder - ACCESS Newswire

NLS Pharmaceutics And Kadimastem Unveil Multi-Target Diabetes Approach - Nasdaq

Is NLSP’s price to cash per share ratio a concern for investors? - US Post News

NLS Pharmaceutics (NLSP) Shares Surge As Market Reacts To Potential Merger - Stocks Telegraph

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies - Marketscreener.com

NLS and Kadimastem to merge, aim for diabetes care innovation - Investing.com

Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews

Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews

NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference - ACCESS Newswire

Dow Edges Lower; Exxon Mobil Earnings Top Views - Benzinga

NLS Pharmaceutics Says Kadimastem Shareholders Approve Merger With NLS; Shares Rise - Marketscreener.com

Nasdaq Jumps Over 150 Points; Apple Posts Upbeat Earnings - Benzinga India

NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice - ACCESS Newswire

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics -January 31, 2025 at 07:31 am EST - Marketscreener.com

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Marketscreener.com

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Benzinga

Nls Pharmaceutics Ag Azioni (NLSPW) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a NLSPW